Business Context and Reporting Period
Company: NeuroOne Medical Technologies Corp (NMTC)
Filing Type: Form 8-K (Current Report)
Date of Report: July 11, 2024
Exchange: The Nasdaq Capital Market
Event: Notice of delisting or failure to satisfy a continued listing rule regarding the minimum bid price requirement.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on regulatory compliance status regarding stock price.
Material Changes and Listing Status
- Non-Compliance Trigger: The closing bid price of the Company's common stock was below $1.00 per share for the prior 30 consecutive business days.
- Regulatory Violation: Failure to meet Nasdaq Marketplace Rule 5550(a)(2) (Minimum Bid Price Requirement).
- Initial Compliance Period: The Company has 180 calendar days from July 11, 2024, until January 7, 2025, to regain compliance.
- Compliance Criteria: The stock must close at or above $1.00 per share for a minimum of 10 consecutive business days within the initial period.
Outlook, Risks, and Management Commentary
- Management Action: The Company intends to actively monitor the closing bid price and consider available options to resolve the deficiency.
- Extension Possibility: If compliance is not met by January 7, 2025, the Company may be eligible for an additional 180-day period if it meets the market value of publicly held shares requirement and other initial listing standards (excluding bid price).
- Delisting Risk: If the Company fails to regain compliance within the allotted time (including extensions), Nasdaq will provide notice that the securities are subject to delisting.
- Appeal Rights: The Company would be entitled to appeal a delisting determination to a Nasdaq hearings panel.
- Uncertainty: There is no assurance that the Company will regain compliance, secure an extension, or maintain other listing requirements.
Investor Verification Checklist
- Verify the current closing bid price of NMTC stock to assess proximity to the $1.00 threshold.
- Monitor the stock's performance over the next 10 consecutive business days to determine if the initial compliance window is met.
- Review the Company's market value of publicly held shares to assess eligibility for a potential second 180-day compliance period.
- Watch for future 8-K filings regarding the Company's specific plan to cure the deficiency (e.g., reverse stock split).
- Check for any announcements regarding an appeal to a Nasdaq hearings panel if delisting is imminent.